Continuous glucose monitor use prevents glycemic deterioration in insulin-treated patients with type 2 diabetes
Karter A, Parker MM ,Moffet HH, et al.
Diabetes Technol Ther. Pub. online 1 Feb 2022.
Leggi
Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper.
Natalicchio A, Faggiano A, Zatelli MC, Argentiero A, D’Oronzo S, Marrano N, Beretta GD, Acquati S, Adinolfi V, Di Bartolo P, Danesi R, Ferrari P, Gori S, Morviducci L, Russo A, Tuveri E, Montagnani M, Gallo M, Silvestris N, Giorgino F
Crit Rev Oncol Hematol. 2022;169:103572.
Leggi
Stress cardiac biomarkers, cardiovascular and renal outcomes, and response to canagliflozin
Vaduganathan M, Sattar N, Xu J, et al.
J Am Coll Cardiol. 2022;79(5):432-44
Leggi
Continuous glucose monitoring in adults with type 1 diabetes with 35 years duration from the DCCT/EDIC Study
Gubitosi-Klug RA, Braffett BH, Bebu I, et al.
Diabetes Care. 2022;dc210629.
Leggi
Risk of incident heart failure in individuals with early-onset type 2 diabetes
Liu JJ, Liu S, Wang J, et al.
J Clin Endocrinol Metab. 2022;107(1):e178-e18.
Leggi
Randomized trial of closed-loop control in very young children with type 1 diabetes
Ware J, Allen JM, Boughton CK, et al.
N Engl J Med. 2022;386(3):209-219.
Leggi
Obesity and chronic kidney disease in US Adults with type 1 and type 2 diabetes mellitus
Wallace AS, Chang AR, Shin JI, et al.
J Clin Endocrinol Metab. 2022;dgab927.
Leggi
Effects of Tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 dabetes
Pirro V, Roth KD, Lin Y, et al.
J Clin Endocrinol Metab. 2022;107(2):363-378.
Leggi